Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290705 | 0.85 | KMT2A (0.71) | BRAFKMT2ATLR7CES1MAPT | |
| SCHEMBL30360592 | 0.85 | KMT2A (0.71) | BRAFKMT2ATLR7CES1MAPT | |
| SCHEMBL4287390 | 0.84 | KDR (0.56) | POLBMAPTKDR | |
| SCHEMBL8215155 | 0.80 | NPC1 (0.51) | MAPT | |
| SCHEMBL4279957 | 0.77 | HDAC3 (0.44) | KMT2ATLR7MAPT | |
| SCHEMBL5269472 | 0.77 | NPC1 (0.58) | KMT2ARXFP1MAPT | |
| SCHEMBL4284549 | 0.76 | NPC1 (0.50) | MAPT | |
| SCHEMBL4284371 | 0.76 | HDAC1 (0.52) | KMT2AMAPTKDR | |
| SCHEMBL4286948 | 0.75 | KMT2A (0.50) | KMT2AMAPTKDR | |
| SCHEMBL4293196 | 0.75 | KMT2A (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | BRAF 32/4885KMT2A 871/4885TLR7 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.